F. Eskens

440 citations

20 papers · 366 indexed · h-index 10

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations

Papers in ⓘ

Oncology 12
- Cancer Treatment and Pharmacology 5
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 3
Molecular Biology 8
- Angiogenesis and VEGF in Cancer 4
- Melanoma and MAPK Pathways 2

Co-authors: Leni van Doorn (6 shared papers)Jaap Verweij (5 shared papers)André Planting (2 shared papers)Elisabeth G.E. de Vries (2 shared papers)Peter Stopfer (2 shared papers)Jourik A. Gietema (2 shared papers)A. Amelsberg (2 shared papers)Holger Huisman (2 shared papers)
Journals: Journal of Clinical Oncology (7 papers)European Journal of Cancer (2 papers)Annals of Oncology (2 papers)British Journal of Cancer (1 paper)Journal of Neuro-Oncology (1 paper)
Partner nations: Netherlands United States Japan

In The Last Decade

F. Eskens

19 papers receiving 357 citations

Peers

Countries citing papers authored by F. Eskens

Since Specialization

Citations

This map shows the geographic impact of F. Eskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Eskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Eskens more than expected).

Fields of papers citing papers by F. Eskens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Eskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Eskens. The network helps show where F. Eskens may publish in the future.

Co-authors

The 25 scholars most cited alongside F. Eskens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F. Eskens Line = papers co-authored together F. Eskens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours British Journal of Cancer ·F. Eskens, Constantijne H. Mom, André Planting, Jourik A. Gietema, A. Amelsberg, Holger Huisman, Leni van Doorn, Henry Burger, Peter Stopfer, Jaap Verweij, Elisabeth G.E. de Vries	2007	202
2	Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide Clinical and Translational Science ·Sander Bins, Leni van Doorn, Mitch A. Phelps, AA Gibson, Shuiying Hu, L Li, A Vasilyeva, Guanting Du, Paul Hamberg, F. Eskens, Peter de Bruijn, Alex Sparreboom, Ron H.J. Mathijssen, Sharyn D. Baker	2017	23
3	A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently Journal of Clinical Oncology ·Maja J.A. deJonge, S. Savage, Jaap Verweij, T. S. Collins, F. Eskens, B. Whitehead, A. Benjamin Suttle, Lini Pandite, Peter Ho, H. Hurwitz	2006	21
4	An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors Journal of Clinical Oncology ·F. Eskens, André Planting, Leni van Doorn, Toshiyuki Isoe, Kunihiko Hayashi, Sunila Hussain, L. Ekman, Horst Bürger, Jaap Verweij	2006	17
5	A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. Journal of Clinical Oncology ·M. Puglisi, Leni van Doorn, Montserrat Blanco-Codesido, Maja J. De Jonge, Kirsty Moran, J. Yang, Todd Busman, Cindy Franklin, M Mabry, Andrew Krivoshik, Rod Humerickhouse, L Rhoda Molife, F. Eskens	2011	17
6	Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus Annals of Oncology ·M. Polée, H.W. Tilanus, F. Eskens, Ronald Hoekstra, M.E.L. van der Burg, Peter D. Siersema, G. Stoter, Ate van der Gaast	2003	14
7	Septic shock caused by group G β-haemolytic streptococci as presenting symptom of acute myeloid leukaemia The Netherlands Journal of Medicine ·F. Eskens	1995	10
8	Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma Journal of Neuro-Oncology ·Martin J. van den Bent, L. Pronk, P.A.E. Sillevis Smitt, Ch.J. Vecht, F. Eskens, Jaap Verweij	1999	9
9	11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer European Journal of Cancer ·Josep Tabernero, Robin M.J.M. van Geel, J.C. Bendell, Anna Spreafico, Martin Schüler, T. Yoshino, J.P. Delord, Yasuhide Yamada, Martijn P. Lolkema, Jason E. Faris, F. Eskens, S. Sharma, Rona Yaeger, H. Lenz, Zev A. Wainberg, Emin Avşar, Arkendu Chatterjee, Savina Jaeger, Tim Demuth, J.H.M. Schellens	2014	9
10	Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin. PubMed ·F. Eskens, E.J.M. Roelofs, A. R. M. M. Hermus, C A Verhagen	1998	9
11	27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors European Journal of Cancer Supplements ·Maja J.A. de Jonge, Neeltje Steeghs, Jaco J. Verweij, J.W.R. Nortier, F. Eskens, Jannemieke Ouwerkerk, Conny van Noort, Patrizia Carpinelli, R. Spinelli, Fabrina Bologna, Hans Gelderblom	2006	7
12	Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Data Archiving and Networked Services (DANS) ·Peter Stopfer, Schaefer Hg, A. Amelsberg, Holger Huisman, F. Eskens, Jourik A. Gietema, James R. Briscoe, Nicole Lewis, R.B. Cohen, John B. Marshall, Jaco J. Verweij	2005	6
13	Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors Journal of Clinical Oncology ·Maja J.A. de Jonge, Neeltje Steeghs, Jaco J. Verweij, J.W.R. Nortier, F. Eskens, Jannemieke Ouwerkerk, B. Laffranchi, Mariangela Mariani, Maria Teresa Rocchetti, Hans Gelderblom	2008	6
14	Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer Journal of Clinical Oncology ·Filip De Vos, Ronald Hoekstra, F. Eskens, Elisabeth G.E. de Vries, Ate van der Gaast, Harry J.M. Groen, Richard Knight, Rod Humerickhouse, J. A. Gietema, Jaap Verweij	2004	4
15	72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors European Journal of Cancer Supplements ·Hans Gelderblom, Jaco J. Verweij, Neeltje Steeghs, Eelco J.P. de Koning, A. van Erkel, Leni van Doorn, Michael Zuehlsdorf, Prabhu Rajagopalan, O. Christensen, F. Eskens	2006	3
16	A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma European Journal of Cancer ·Marlies H.G. Langenberg, Larry Gluck, Vincent A. de Weger, Robert Frank, F. Eskens, Jean‐Yves Blay, J.C. Soria, Sant P. Chawla, Murugesan Gounder, Amy J. Wagner, Y. Zhang, Pritam Kambuj, Robert D. Loberg, Haby Henary	2016	3
17	Phase I, safety, pharmacokinetic and biomarker study of BAY 57–9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors Journal of Clinical Oncology ·Hans Gelderblom, Jaco J. Verweij, Neeltje Steeghs, A. van Erkel, Leni van Doorn, Jannemieke Ouwerkerk, Prabhu Rajagopalan, A. Matthys, D. Voliotis, F. Eskens	2006	3
18	Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) Annals of Oncology ·Omid Hamid, Siwen Hu‐Lieskovan, Willeke Ros, Adi Diab, Anthony B. El-Khoueiry, John A. Thompson, F. Eskens, J.-P. Spano, Eric Angevin, Naiyer A. Rizvi, Jeffrey S. Wasser, Patrick A. Ott, Alberto Chiappori, Tenshang Joh, Heike I. Krupka, Shobha Potluri, X. Wang, Bishu J. Ganguli, Jeffrey Chou, Toshihiko Doi	2018	2
19	344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors European Journal of Cancer Supplements ·C. van Herpen, F. Eskens, M. de Jonge, Ingrid M.E. Desar, Leon Hooftman, Elisabeth A. Bone, Anja Timmer-Bonte, Jaco J. Verweij	2008	1
20	VEGF, sVEGFR-2, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57–9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors Journal of Clinical Oncology ·Michael Zuehlsdorf, O. Christensen, Dirk Strumberg, K. Mross, F. Eskens, Hans Gelderblom, Jaco J. Verweij, Prabhu Rajagopalan, D. Voliotis, Georg Wensing	2006	0

About F. Eskens

F. Eskens is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Surgery, having authored 20 papers that have together received 366 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers), Angiogenesis and VEGF in Cancer (4 papers), HER2/EGFR in Cancer Research (3 papers), Melanoma and MAPK Pathways (2 papers), Cancer Genomics and Diagnostics (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Oncology (244 citations), Pulmonary and Respiratory Medicine (189 citations), Genetics (40 citations), Hematology (25 citations) and Molecular Biology (153 citations). F. Eskens has collaborated with scholars based in Netherlands, United States and Japan. Frequent co-authors include Leni van Doorn, Jaap Verweij, André Planting, Elisabeth G.E. de Vries, Peter Stopfer, Jourik A. Gietema, A. Amelsberg, Holger Huisman, Henry Burger and Constantijne H. Mom. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and Journal of Neuro-Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact